In Mild Strokes, Ultra-Early Treatment May Eliminate Risk Of Disability
The American Heart Association/American Stroke Association recommends getting to a hospital within three hours of the onset of stroke symptoms. According to guidelines, clot-busting drugs may be given to treat stroke up to 4.5 hours after the onset of symptoms.
The study found that survivors with mild to moderate strokes who were given the clot-busting drugs in the first 90 minutes of the recommended time window had little or no disability three months later compared to those who were treated between 90 and 270 minutes.
“Ultra-early treatment increases the likelihood of excellent outcome in patients with moderately severe symptoms, and in secondary analysis also in those with mild symptoms,” said Daniel Strbian, M.D., Ph.D., from the Department of Neurology at Helsinki University Central Hospital in Helsinki, Finland. “All measures must be taken to reduce onset-to-treatment time as much as possible.”
The study included more than 6,800 stroke patients at 10 stroke centers in Europe over 14 years. They were treated intravenously with Alteplase, a clot-busting drug that is given through an IV in the vein. Patients were separated into three groups based on stroke severity – minor (NIH stroke score 0-6), mild/moderate (NIH score 7-12), or moderate/severe (NIH score higher than 12). Those with mild to moderate stroke seemed to benefit most from the ultra-early care. Early treatment also helped those with minor strokes, but the likelihood of disability is already very low in these patients.
Those with severe stroke did not benefit as much from the ultra-early treatment because they had severe artery blockage.
“We need more research to offer something more for people with severe strokes,” Strbian said.
Source: The American Heart Association/American Stroke Association
Published on : Thu, 29 Aug 2013
Medos customized tubing sets have been individually designed, so that all customer requirements, depending on application and need can be realized. Furthermore tubing sets can be refined by rheoparin or x.eed coating.
Stay informed at every point of care In compliance with out-of-hospital patient transport standards such as EN1789, EN13718-1, IEC60601-1-12 and U.S. military standards, N1 is a highly competent solution for various out-of-hospital transport settings...
The HAMILTON-G5 is Hamilton Medical’s most modular high-end mechanical ventilator. A wide range of standard features and options allows you to tailor the HAMILTON-G5 to your needs. · Automated control of the patient’s ventilation a
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...